Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Breast Cancer
•
Medical Oncology
•
Breast Cancer, Non-metastatic
What adjuvant therapy would you offer a TNBC patient with residual disease after receiving the neoadjuvant KEYNOTE-522 regimen?
Answer from: Medical Oncologist at Academic Institution
Safety is pembro and cape was provided in phase I trials. Risk and benefit weighing is important when discussing with patients.
Sign in or Register to read more
12421
Related Questions
Would you offer adjuvant abemaciclib to young, premenopausal women desiring more children who meet criteria for the same based on monarchE trial?
How do you approach ovarian function suppression in premenopausal women with HR+/HER2-, node negative breast cancer and intermediate OncoType dx scores (11-25) who received chemotherapy?
What are your top takeaways in Breast Cancer from ASCO 2023?
How do you approach adjuvant therapy to minimize cardiotoxicity in early stage node negative HER2+ HR+ breast cancer with history of chest wall radiation and previous cardiotoxic agents for Hodgkin Lymphoma?
Do you approach systemic therapy any differently for patients with locally advanced relapses of TNBC with metaplastic squamous differentiation, as opposed to patients with TNBC?
Which chemotherapy is preferred between TC and AC-T in a young patient with ER+/PR+/HER2- node negative breast cancer, intermediate grade, with high OncoType score?
How would you approach a cT4 cN2 (22 cm in size) TNBC that shrank to 9 cm with KN-522 regimen but remains inoperable at the end of treatment?
Would you offer adjuvant endocrine therapy to a male with ER+ DCIS?
Do you modify your choice of systemic therapy for localized early stage ER+/PR+ HER2- breast if Mammaprint shows basal subtype?
Does HER2 status or response to neoadjuvant therapy influence your decision to use ovarian function suppression in premenopausal patients with ER+ HER2+ tumors?